MX2022006824A - Nanoesferas de plga cargadas con proteinas. - Google Patents

Nanoesferas de plga cargadas con proteinas.

Info

Publication number
MX2022006824A
MX2022006824A MX2022006824A MX2022006824A MX2022006824A MX 2022006824 A MX2022006824 A MX 2022006824A MX 2022006824 A MX2022006824 A MX 2022006824A MX 2022006824 A MX2022006824 A MX 2022006824A MX 2022006824 A MX2022006824 A MX 2022006824A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery vector
therapeutic substance
protein
solution
Prior art date
Application number
MX2022006824A
Other languages
English (en)
Spanish (es)
Inventor
Brock A Lindsey
Justin E Markel
Ryan A Lacinski
Jabeen Noore
Original Assignee
Univ West Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ West Virginia filed Critical Univ West Virginia
Publication of MX2022006824A publication Critical patent/MX2022006824A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2022006824A 2019-12-05 2020-12-04 Nanoesferas de plga cargadas con proteinas. MX2022006824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944191P 2019-12-05 2019-12-05
PCT/US2020/063314 WO2021113638A1 (en) 2019-12-05 2020-12-04 Protein-loaded plga nanospheres

Publications (1)

Publication Number Publication Date
MX2022006824A true MX2022006824A (es) 2022-09-19

Family

ID=76221229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006824A MX2022006824A (es) 2019-12-05 2020-12-04 Nanoesferas de plga cargadas con proteinas.

Country Status (11)

Country Link
US (3) US12214046B2 (cg-RX-API-DMAC7.html)
EP (1) EP4072536A4 (cg-RX-API-DMAC7.html)
JP (2) JP7818514B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220143811A (cg-RX-API-DMAC7.html)
CN (1) CN115335041A (cg-RX-API-DMAC7.html)
AU (1) AU2020396557B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010952A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160922A1 (cg-RX-API-DMAC7.html)
IL (1) IL293607A (cg-RX-API-DMAC7.html)
MX (1) MX2022006824A (cg-RX-API-DMAC7.html)
WO (1) WO2021113638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006824A (es) 2019-12-05 2022-09-19 Univ West Virginia Nanoesferas de plga cargadas con proteinas.
CN116855571B (zh) * 2023-06-26 2025-03-21 中国农业大学 Plga纳米球病毒示踪剂及其制备方法与应用
KR20250069077A (ko) * 2023-11-10 2025-05-19 아주대학교산학협력단 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20040003402A1 (en) 2002-06-27 2004-01-01 Digeo, Inc. Method and apparatus for automatic ticker generation based on implicit or explicit profiling
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
WO2005023293A1 (en) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
EP1985309B1 (en) 2005-12-26 2016-11-23 LTT Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
DK2251006T3 (en) 2008-02-22 2017-10-16 Toray Industries Microparticles and pharmaceutical compositions thereof
US9972047B1 (en) 2008-04-18 2018-05-15 Capital One Services, Llc Systems and methods for performing a purchase transaction using rewards points
US20090281888A1 (en) 2008-05-09 2009-11-12 Li-Cheng Richard Zai Method And Apparatus For Establishing Time-Based Loyalty Relationship
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
WO2011063177A1 (en) 2009-11-20 2011-05-26 Mobisave Corporation System and method of electronically verifying required proof-of-performance to secure promotional rewards
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
WO2012051220A1 (en) * 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
RU2014112958A (ru) * 2011-09-21 2015-10-27 Йиссум Ресерч Девелопмент Компани оф де Хебрю Юниверсити оф Джерусалем Лтд. Наносистемы доставки для мирнк
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
US9610250B2 (en) * 2012-04-12 2017-04-04 Yale University Nanolipogel vehicles for controlled delivery of different pharmaceutical agents
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
US9724304B2 (en) 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
US9308172B2 (en) 2012-10-26 2016-04-12 Board Of Trustees Of Michigan State University Device and method for encapsulation of hydrophilic materials
KR20190126452A (ko) * 2013-11-01 2019-11-11 예일 유니버시티 면역요법용 모듈러 입자
US10272050B2 (en) * 2014-10-14 2019-04-30 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
CN104622795B (zh) * 2015-01-28 2017-12-08 杭州市萧山区中医院 一种多细胞因子序贯缓释微球‑水凝胶复合系统及其制备方法
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
KR102717886B1 (ko) * 2018-02-26 2024-10-16 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 약물 전달 시스템
CA3141275A1 (en) 2019-06-18 2020-12-24 Biomeme, Inc. Systems for sample analysis
MX2022006824A (es) 2019-12-05 2022-09-19 Univ West Virginia Nanoesferas de plga cargadas con proteinas.

Also Published As

Publication number Publication date
US20250064949A1 (en) 2025-02-27
CN115335041A (zh) 2022-11-11
EP4072536A1 (en) 2022-10-19
EP4072536A4 (en) 2025-01-15
WO2021113638A1 (en) 2021-06-10
BR112022010952A2 (pt) 2022-09-06
JP2026077709A (ja) 2026-05-13
AU2020396557B2 (en) 2026-05-14
AU2020396557A1 (en) 2022-06-23
US20250073343A1 (en) 2025-03-06
US12214046B2 (en) 2025-02-04
JP2023504282A (ja) 2023-02-02
JP7818514B2 (ja) 2026-02-20
US20230070180A1 (en) 2023-03-09
IL293607A (en) 2022-08-01
CA3160922A1 (en) 2021-06-10
KR20220143811A (ko) 2022-10-25

Similar Documents

Publication Publication Date Title
AU2024200841B2 (en) Compositions and methods for treating diseases and disorders of the central nervous system
Xu et al. Induction of osteogenesis by bone-targeted Notch activation
US9944910B2 (en) TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
JP2015520161A5 (cg-RX-API-DMAC7.html)
KR20220128362A (ko) 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태
US11603394B2 (en) Targeted effector proteins and uses thereof
CN111032075A (zh) 用于治疗癌症的方法和组合物
CN109153720B (zh) 使用CLEVER-1、TNF-α和HLA-DR结合剂的免疫活化的诊断
WO2022061094A1 (en) Solid dosage forms of bacteria
BR112022010952A2 (pt) Nanosferas de plga carregadas de proteína
KR20230019109A (ko) Akt3 조절제 및 이의 사용 방법
Tiewcharoen et al. Effect of synthetic antimicrobial peptides on Naegleria fowleri trophozoites
US20130303596A1 (en) Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies
Cerecedo et al. Platelet adhesion: structural and functional diversity of short dystrophin and utrophins in the formation of dystrophinassociated-protein complexes related to actin dynamics
Brifault et al. The neuropeptide PACAP, a potent disease modifier candidate for brain stroke treatment
KR101748120B1 (ko) 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
KR20240093504A (ko) 박테리아 및 미생물 세포외 소포를 함유하는 고체 투여 형태
WO2014022685A1 (en) Recruitment of mesenchymal cells using controlled release systems
CN107722111A (zh) 一种巨噬细胞吞噬能力促进剂
CN118576624A (zh) 一种自溶沙门氏菌-纳米胶囊输送系统、免疫刺激水凝胶及其应用
AU2017218918A1 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
HK40084846A (en) Akt3 modulators and methods of use thereof
Galoyan et al. Study of the genotoxic effects of a proline-rich polypeptide using the comet assay
HK1261998B (en) Diagnosis of immune activation using clever-1, tnf-alpha and hla-dr binding agents